The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

Article Microbiology

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Robert M. Cox et al.

Summary: Treating SARS-CoV-2-infected ferrets with nucleoside analogue MK-4482/EIDD-2801 reduced viral load and suppressed virus spread. This therapeutic approach shows promise in breaking transmission chains of the COVID-19 pandemic.

NATURE MICROBIOLOGY (2021)

添加到收藏夹

Article Microbiology

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

Wendy P. Painter et al.

Summary: Molnupiravir showed rapid appearance and dose-proportional increase in plasma, with good tolerability in healthy volunteers. The study evaluated single and multiple doses of molnupiravir and the impact of food on pharmacokinetics in subjects, showing no accumulation following multiple doses and a decrease in absorption rate when administered with food, but no decrease in overall exposure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Angela Wahl et al.

Summary: The study suggests that bats may be the source of coronaviruses that can be directly transmitted to humans. Using the LoM model, efficient replication of SARS-CoV, MERS-CoV, SARS-CoV-2, and two SARS-like bat coronaviruses in human lung tissue was demonstrated. Infection with SARS-CoV-2 predominantly targets human lung epithelial cells and induces a sustained inflammatory response. The broad-spectrum antiviral agent EIDD-2801 significantly inhibits SARS-CoV-2 replication in vivo, showing potential for prevention and treatment of COVID-19.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

Jean-Selim Driouich et al.

Summary: Despite limited pre-clinical evidence, repurposed drugs such as favipiravir are being extensively evaluated in clinical trials to combat the lack of antiviral options against SARS-CoV-2. Favipiravir shows strong antiviral efficacy in a Syrian hamster model, with high doses reducing viral infectivity while inducing mutations in viral genomes. However, toxicity concerns are noted at the highest tested dose, requiring further pharmacokinetic and tolerance studies before potential human use.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Kyle Rosenke et al.

Summary: Orally administered nucleoside analog MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model, with an inhibitory effect observed whether the drug is given 12 hours before or 12 hours after infection. This suggests the potential of MK-4482 for controlling SARS-CoV-2 infection in humans following high-risk exposure and for treating COVID-19 patients.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Microbiology

Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus

Jennifer Mayor et al.

Summary: Ecological changes, population movements, and increasing urbanization contribute to the spread of hantaviruses, posing a high risk of virus transmission and diseases to humans; Ribavirin is currently the only antiviral medication used to treat HFRS caused by HTNV, but with severe side effects; Favipiravir has shown similar potent antiviral activity on HTNV infection, and when used in combination with low-dose ribavirin, its efficacy is enhanced, suggesting the potential for improved treatment.

MICROORGANISMS (2021)

添加到收藏夹

Article Medicine, General & Internal